• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4602291)   Today's Articles (42)   Subscriber (49368)
For: Gronlund B, Høgdall C, Hilden J, Engelholm SA, Høgdall EVS, Hansen HH. Should CA-125 Response Criteria Be Preferred to Response Evaluation Criteria in Solid Tumors (RECIST) for Prognostication During Second-Line Chemotherapy of Ovarian Carcinoma? J Clin Oncol 2004;22:4051-8. [PMID: 15364966 DOI: 10.1200/jco.2004.10.028] [Citation(s) in RCA: 65] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]  Open
Number Cited by Other Article(s)
51
Coleman RL, Gordon A, Barter J, Sun S, Rackoff W, Herzog TJ. Early Changes in CA125 After Treatment with Pegylated Liposomal Doxorubicin or Topotecan Do Not Always Reflect Best Response in Recurrent Ovarian Cancer Patients. Oncologist 2007;12:72-8. [PMID: 17227902 DOI: 10.1634/theoncologist.12-1-72] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]  Open
52
Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2006;102:140-4. [PMID: 16790264 DOI: 10.1016/j.ygyno.2006.05.006] [Citation(s) in RCA: 115] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2006] [Revised: 04/28/2006] [Accepted: 05/03/2006] [Indexed: 01/16/2023]
53
Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG. Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol 2006;103:637-41. [PMID: 16781766 DOI: 10.1016/j.ygyno.2006.04.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2005] [Revised: 04/13/2006] [Accepted: 04/25/2006] [Indexed: 10/24/2022]
54
Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol 2006;103:212-8. [PMID: 16677696 DOI: 10.1016/j.ygyno.2006.02.026] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2005] [Revised: 02/16/2006] [Accepted: 02/21/2006] [Indexed: 11/28/2022]
55
Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031-9. [PMID: 16616487 DOI: 10.1016/j.ejca.2006.01.026] [Citation(s) in RCA: 326] [Impact Index Per Article: 18.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2006] [Accepted: 01/24/2006] [Indexed: 12/16/2022]
56
Kurosaki H, Oriuchi N, Okazaki A, Tamaki T, Uki A, Izuta M, Kojima R, Kato Y, Higuchi T, Maruno H. Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment. Ann Nucl Med 2006;20:171-4. [PMID: 16715946 DOI: 10.1007/bf03027426] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
57
Granai CO. All by itself. Gynecol Oncol 2006;101:1-3. [PMID: 16504754 DOI: 10.1016/j.ygyno.2006.01.043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
58
Palmer C, Pratt J, Basu B, Earl H. A study to evaluate the use of CA125 in ovarian cancer follow-up: A change in practice led by patient preference. Gynecol Oncol 2006;101:4-11. [PMID: 16445969 DOI: 10.1016/j.ygyno.2005.11.046] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2005] [Revised: 11/19/2005] [Accepted: 11/30/2005] [Indexed: 11/26/2022]
59
Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, Delva R, Lotz JP, Belle SV, Extra JM, Cvitkovic E. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol 2006;17:429-36. [PMID: 16500913 DOI: 10.1093/annonc/mdj097] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]  Open
60
Dizon DS, Weitzen S, Rojan A, Schwartz J, Miller J, Disilvestro P, Gordinier ME, Moore R, Tejada-Berges T, Pires L, Legare R, Granai CO. Two for good measure: six versus eight cycles of carboplatin and paclitaxel as adjuvant treatment for epithelial ovarian cancer. Gynecol Oncol 2005;100:417-21. [PMID: 16336992 DOI: 10.1016/j.ygyno.2005.10.031] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2005] [Revised: 10/17/2005] [Accepted: 10/24/2005] [Indexed: 11/23/2022]
61
Berkenblit A, Matulonis UA, Kroener JF, Dezube BJ, Lam GN, Cuasay LC, Brünner N, Jones TR, Silverman MH, Gold MA. A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol 2005;99:50-7. [PMID: 16023182 DOI: 10.1016/j.ygyno.2005.05.023] [Citation(s) in RCA: 55] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2005] [Revised: 04/29/2005] [Accepted: 05/06/2005] [Indexed: 11/24/2022]
62
Ferretti S, Allegrini PR, O'Reilly T, Schnell C, Stumm M, Wartmann M, Wood J, McSheehy PMJ. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 2005;11:7773-84. [PMID: 16278399 DOI: 10.1158/1078-0432.ccr-05-1165] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
63
Rettenmaier MA, Goldstein BH, Stallman JM, Brown JV, Micha JP. Greatly Elevated Serum CA-125 Level in a Patient with a Ruptured Endometrioma. J Gynecol Surg 2005. [DOI: 10.1089/gyn.2005.21.117] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
64
Sundar S, O'Byrne KJ. CA-125 criteria for response evaluation in ovarian cancer. Gynecol Oncol 2005;98:520-1. [PMID: 15913743 DOI: 10.1016/j.ygyno.2005.07.021] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2005] [Revised: 01/27/2005] [Accepted: 03/09/2005] [Indexed: 10/25/2022]
65
Ozols RF. Treatment goals in ovarian cancer. Int J Gynecol Cancer 2005;15 Suppl 1:3-11. [PMID: 15839952 DOI: 10.1111/j.1525-1438.2005.15351.x] [Citation(s) in RCA: 173] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]  Open
PrevPage 2 of 2 12Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA